TOP HEADLINES

Featured Story

  • Cancer vaccines report mixed fortunes at ASCO

    At the cancer conference ASCO, researchers reported weak Phase III results for a telomerase peptide vaccine, GV1001, in pancreatic cancer patients. Most other cancer vaccines presented at the conference are at earlier stages of development.

Latin American cancer vax races Big Pharma rivals

The lung cancer vaccine race has brought together an unusual mix of players. Merck KGaA was in a good position, but its vaccine disappointed in Phase III, while GlaxoSmithKline could report data on its candidate this year. Then there is the Cuba-Argentina joint venture.

Oral vaccine aims to end dreaded Delhi belly

Researchers at the University of Cambridge are talking up the potential of a vaccine to stop traveler's diarrhea.

Dynavax shares spike on promising Heplisav data

Shares of Dynavax Technologies soared 35 percent after the developer announced that its hepatitis B vaccine Heplisav produced promising data in a mid-stage study, protecting patients with chronic

HHS weighs H7N9 vaccine stockpiling options

Stockpiling vaccines requires authorities to peek into the future. When H1N1 was causing panic in 2009, the U.S. predicted it would need 160 million vaccine doses. But demand never took off, and the U.S. destroyed 40 million out-of-date vaccines in 2010.

Gates-backed vaccine slashes African meningitis deaths

In the first 5 months of 2013, 857 deaths were reported in countries under enhanced surveillance.

MORE NEWS

From Our Sister Sites

FierceBiotech

Biotech IPOs are officially back in vogue. Bluebird bio--set up to develop new gene therapies for orphan diseases--priced its IPO at $17 a share, actually above its range. The biotech raised $101...

FierceDrugDelivery

Indian researchers have created strings of nanoparticles--called nano-necklaces--that can be programmed to deliver drugs to very specific targets in the body via chemical propulsion.